Nintedanib ameliorates animal model of dermatitis.
Min-Jeong HeoChanmi LeeSoo Young ChoiYeong Min ChoiIn-Sook AnSeunghee BaeSungkwan AnJin Hyuk JungPublished in: Scientific reports (2020)
Nintedanib, a receptor tyrosine kinase (RTK) inhibitor has been developed as therapeutics for idiopathic pulmonary fibrosis and non-small lung cancer. We found that the expression levels of RTK, especially VEGFR1 is increased in skin biopsies of dermatitis patients from multiple independent datasets. Moreover, VEGFR1 is highly expressed by infiltrated cells in dermis from oxazolone (OXA) treated mice. Interestingly, nintedanib alleviates dermatitis symptom in OXA-induced animal model. Especially, levels of epidermis thickness, infiltrated immune cells including mast cells and eosinophils were decreased from mice cotreated with nintedanib and OXA compared with OXA treated mice. Moreover, serum IgE and Th2 cytokines including IL-4 and IL-13 were decreased by nintedanib treatment. These results suggest an evidence that nintedanib alleviates animal model of dermatitis.
Keyphrases
- idiopathic pulmonary fibrosis
- tyrosine kinase
- acinetobacter baumannii
- klebsiella pneumoniae
- interstitial lung disease
- high fat diet induced
- newly diagnosed
- epidermal growth factor receptor
- atopic dermatitis
- mouse model
- ejection fraction
- induced apoptosis
- poor prognosis
- drug resistant
- type diabetes
- binding protein
- optical coherence tomography
- prognostic factors
- small molecule
- escherichia coli
- adipose tissue
- patient reported outcomes
- oxidative stress
- signaling pathway
- cell cycle arrest
- endothelial cells
- systemic sclerosis